LIA
APLS

LSP Investment Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

LSP Investment Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,500
Closed -$249K – 31
2022
Q2 		$249K Hold
5,500
– – 0.1% 30
2022
Q1 		$279K Hold
5,500
– – 0.08% 28
2021
Q4 		$260K Buy
+5,500
New +$217K 0.11% 28

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

LSP Investment Advisors's APLS Position: Q3 2022 in Review

LSP Investment Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 5,500 shares — an estimated $249K sold.

LSP Investment Advisors first reported a position in APLS in Q4 2021 and held it in 3 quarters. The position peaked at $279K in Q1 2022. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

  • LSP Investment Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • LSP Investment Advisors sold 5,500 Apellis Pharmaceuticals shares in Q3 2022, an estimated $249K.
  • LSP Investment Advisors first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • LSP Investment Advisors's Apellis Pharmaceuticals position peaked at $279K in Q1 2022.
  • 250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on LSP Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.